Cancer drug combo trial halted after just one patient
NCT ID NCT06130254
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 34 times
Summary
This early-phase trial aimed to test the safety of combining two targeted drugs, adagrasib and olaparib, in people with advanced solid tumors that have a specific KRAS G12C mutation. The study planned to include patients with gynecological, breast, pancreatic, and certain lung cancers. However, the trial was terminated after enrolling only one participant, so no conclusions can be drawn about the combination's safety or effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
adagrasib and olaparib
What this could lead to
If it worked, this combination might offer a new treatment option for certain hard-to-treat cancers with a specific gene mutation.
What could go wrong
The trial was terminated after enrolling only 1 person, so there is no meaningful data on safety or effectiveness. It is too early to draw any conclusions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.